analyst
AN
NASDAQ · ANNX
Annexon, Inc.
Healthcare · Biotechnology
$5.25
Down-$0.28 (-5.33%)
Updated Aug 28, 2026, 10:32 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 669.73M
- P/E ratio
- -4.03
- Dividend yield
- 0.00%
- 52-week range
- $4.46 – $6.62
- Volume
- 3.02M
- Avg. volume
- 2.57M
Price performance
ANNX price history
1M range · 21 trading sessions · Daily adjusted prices
ANNX closed at $5.25 after 21 trading sessions, down 0.38% for the selected period.
- Last close
- $5.25
- Period change
- -0.38%
- Period low
- $4.99
- Period high
- $5.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $5.00 | $5.32 | $4.91 | $5.25 | 3.02M |
| Aug 26, 2026 | $5.13 | $5.175 | $4.955 | $4.99 | 2.28M |
| Aug 25, 2026 | $5.13 | $5.225 | $5.085 | $5.15 | 2.94M |
| Aug 24, 2026 | $5.05 | $5.13 | $4.80 | $5.06 | 3.38M |
| Aug 21, 2026 | $5.24 | $5.275 | $5.02 | $5.07 | 1.43M |
| Aug 20, 2026 | $5.41 | $5.465 | $5.105 | $5.18 | 1.67M |
| Aug 19, 2026 | $5.45 | $5.59 | $5.34 | $5.50 | 3.5M |
| Aug 18, 2026 | $5.03 | $5.3078 | $5.02 | $5.28 | 2.24M |
| Aug 17, 2026 | $5.26 | $5.29 | $5.06 | $5.13 | 3.63M |
| Aug 14, 2026 | $5.21 | $5.345 | $5.081 | $5.29 | 2.99M |
| Aug 13, 2026 | $5.36 | $5.40 | $5.195 | $5.26 | 3.12M |
| Aug 12, 2026 | $5.06 | $5.415 | $5.00 | $5.33 | 3.95M |
| Aug 11, 2026 | $5.40 | $5.45 | $5.165 | $5.34 | 924.8K |
| Aug 10, 2026 | $5.39 | $5.505 | $5.265 | $5.39 | 1.96M |
| Aug 7, 2026 | $5.63 | $5.70 | $5.39 | $5.41 | 2.05M |
| Aug 6, 2026 | $5.37 | $5.60 | $5.37 | $5.60 | 3.05M |
| Aug 5, 2026 | $5.40 | $5.43 | $5.26 | $5.37 | 1.77M |
| Aug 4, 2026 | $5.35 | $5.48 | $5.255 | $5.33 | 2.56M |
| Aug 3, 2026 | $5.07 | $5.27 | $4.89 | $5.25 | 2.69M |
| Jul 31, 2026 | $5.37 | $5.40 | $5.025 | $5.095 | 2.8M |
| Jul 30, 2026 | $4.88 | $5.295 | $4.83 | $5.27 | 2.61M |
Latest ANNX news
The latest Smart Investors Daily articles mentioning ANNX.
Stock researchCompany · Dividend
Loading stock research…

